Recently, De Cunto et al. addressed a big contribution of S1P in airways pathology and COPD development in a mouse CS model, they demonstrated the therapeutic potential of S1P inhibitors in controlling emphysema-related airways hyperresponsiveness in smokers with both asthma and COPD [14]. This evidence concerns the gene MBTPS1 and chronic obstructive pulmonary disease.